Arylsulfonamides as orexin receptor agonists

A compound of Formula (I):

• or deuterated forms or a pharmaceutically acceptable salt thereof,
• wherein
• A is C2-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, or divalent 4-to 7-membered cycloalkyl, heterocyclyl ring, optionally with one or more degrees of unsaturation, and containing 1 to 3 heteroatoms selected from the group consisting of O, N, or S;
• B is C2-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, or divalent 4-to 7-membered cycloalkyl, heterocyclyl ring, optionally with one or more degrees of unsaturation, and containing 1 to 3 heteroatoms selected from the group consisting of O, N, or S;
• R1 is (CH2)m-heteroaryl;
• m is 0, 1, 2, 3, 4, 5, or 6;
• R2 is hydrogen or C1-6 alkyl;
• X is a bond, O, C(O), NH, NHC(O), or C(O)NH;
• Y is a bond, C2-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, divalent 4-to 7-membered cycloalkyl ring, optionally with one or more degrees of unsaturation, or divalent 4-to 7-membered heterocyclyl ring, optionally with one or more degrees of unsaturation, and containing 1 to 3 heteroatoms selected from the group consisting of O, N, or S;
• Z is a bond, O, C(O), NH, NHC(O), or C(O) NH;
• R3 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, (CH2)n-C3-6 cycloalkyl, (CH2)n-phenyl, (CH2)n-naphthyl, or (CH2)n-(4-to 7-membered heterocyclyl ring), where such ring optionally has one or more degrees of unsaturation, and contains 1 to 3 heteroatoms selected from the group consisting of O, N, or S,
• wherein each R3 may be substituted with one or more substituent selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C1-6 haloalkyl, C2-6 haloalkenyl, C2-6 haloalkynyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, CN, NO2, OH, O(C1-6 alkyl), SH, S (C1-6 alkyl), and ═O;
• and
• each n is independently 0, 1, 2, or 3.